Clinical trial
A Phase II Randomized Study Evaluating the Biological and Clinical Effects of the Combination of Palbociclib With Letrozole as Neoadjuvant Therapy in Post-Menopausal Women With Estrogen-Receptor Positive Primary Breast Cancer
NCT02296801 is registered in ClinicalTrials.gov with NSABP Foundation Inc as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase II Randomized Study Evaluating the Biological and Clinical Effects of the Combination of Palbociclib With Letrozole as Neoadjuvant Therapy in Post-Menopausal Women With Estrogen-Receptor Positive Primary Breast Cancer
- Lead sponsor
- NSABP Foundation Inc
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- January 31, 2015
- Completion date
- March 31, 2019
- Enrollment
- 307 (actual)
- Sites
- 52
Conditions
As the registry lists them; a condition with its own page is linked.
breast cancer, breast carcinoma, breast tumors